These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 29875732)

  • 21. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1.
    Ward AJ; Rimer M; Killian JM; Dowling JJ; Cooper TA
    Hum Mol Genet; 2010 Sep; 19(18):3614-22. PubMed ID: 20603324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myotonic dystrophy: emerging mechanisms for DM1 and DM2.
    Cho DH; Tapscott SJ
    Biochim Biophys Acta; 2007 Feb; 1772(2):195-204. PubMed ID: 16876389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2.
    Timchenko L
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific
    Porquet F; Weidong L; Jehasse K; Gazon H; Kondili M; Blacher S; Massotte L; Di Valentin E; Furling D; Gillet NA; Klein AF; Seutin V; Willems L
    Mol Ther Nucleic Acids; 2023 Jun; 32():857-871. PubMed ID: 37273786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome Editing of Expanded CTG Repeats within the Human DMPK Gene Reduces Nuclear RNA Foci in the Muscle of DM1 Mice.
    Lo Scrudato M; Poulard K; Sourd C; Tomé S; Klein AF; Corre G; Huguet A; Furling D; Gourdon G; Buj-Bello A
    Mol Ther; 2019 Aug; 27(8):1372-1388. PubMed ID: 31253581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dysregulation of GSK3β-Target Proteins in Skin Fibroblasts of Myotonic Dystrophy Type 1 (DM1) Patients.
    Grande V; Hathazi D; O'Connor E; Marteau T; Schara-Schmidt U; Hentschel A; Gourdon G; Nikolenko N; Lochmüller H; Roos A
    J Neuromuscul Dis; 2021; 8(4):603-619. PubMed ID: 33682722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Drosophila model of myotonic dystrophy type 1: phenotypic characterization and genome-wide view of altered gene expression.
    Picchio L; Plantie E; Renaud Y; Poovthumkadavil P; Jagla K
    Hum Mol Genet; 2013 Jul; 22(14):2795-810. PubMed ID: 23525904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac involvement in patient-specific induced pluripotent stem cells of myotonic dystrophy type 1: unveiling the impact of voltage-gated sodium channels.
    Pierre M; Djemai M; Chapotte-Baldacci CA; Pouliot V; Puymirat J; Boutjdir M; Chahine M
    Front Physiol; 2023; 14():1258318. PubMed ID: 37791351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcriptome changes in DM1 patients' tissues are governed by the RNA interference pathway.
    Braun M; Shoshani S; Tabach Y
    Front Mol Biosci; 2022; 9():955753. PubMed ID: 36060259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deciphering the mechanisms underlying brain alterations and cognitive impairment in congenital myotonic dystrophy.
    De Serres-Bérard T; Pierre M; Chahine M; Puymirat J
    Neurobiol Dis; 2021 Dec; 160():105532. PubMed ID: 34655747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GSK3β is a new therapeutic target for myotonic dystrophy type 1.
    Wei C; Jones K; Timchenko NA; Timchenko L
    Rare Dis; 2013; 1():e26555. PubMed ID: 25003008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1.
    Wojciechowska M; Taylor K; Sobczak K; Napierala M; Krzyzosiak WJ
    RNA Biol; 2014; 11(6):742-54. PubMed ID: 24824895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GSK3β mediates muscle pathology in myotonic dystrophy.
    Jones K; Wei C; Iakova P; Bugiardini E; Schneider-Gold C; Meola G; Woodgett J; Killian J; Timchenko NA; Timchenko LT
    J Clin Invest; 2012 Dec; 122(12):4461-72. PubMed ID: 23160194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis genes.
    Cerro-Herreros E; Chakraborty M; Pérez-Alonso M; Artero R; Llamusí B
    Sci Rep; 2017 Jun; 7(1):2843. PubMed ID: 28588248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular and clinical characteristics of myotonic dystrophy type 1 in koreans.
    Kim SY; Kim JY; Kim GP; Sung JJ; Lim KS; Lee KW; Chae JH; Hong YH; Seong MW; Park SS
    Korean J Lab Med; 2008 Dec; 28(6):483-92. PubMed ID: 19127114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy.
    Lutz M; Levanti M; Karns R; Gourdon G; Lindquist D; Timchenko NA; Timchenko L
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445828
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Visconti VV; Macrì E; D'Apice MR; Centofanti F; Massa R; Novelli G; Botta A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pathogenesis of myotonic dystrophy type 1].
    Magaña JJ; Leyva-García N; Cisneros B
    Gac Med Mex; 2009; 145(4):331-7. PubMed ID: 20073433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice.
    Jauvin D; Chrétien J; Pandey SK; Martineau L; Revillod L; Bassez G; Lachon A; MacLeod AR; Gourdon G; Wheeler TM; Thornton CA; Bennett CF; Puymirat J
    Mol Ther Nucleic Acids; 2017 Jun; 7():465-474. PubMed ID: 28624222
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.